ZTS
US EQUITY
Health Care
Pharmaceuticals
CIK: 1555280
Zoetis (ZTS) Quant Factor Diagnostic & Fair Value Model
Zoetis (Ticker: ZTS) is listed in the Health Care sector (Pharmaceuticals). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$81.03
-1.18%
Latest Close (2026-10-23)
Market Cap: $33.48B
P/E Ratio: 12.3
Momentum Strength
3M / 12M
+5.34%
1M: +15.31%
12M: -44.92%
Quality (ROE)
Point-in-Time
+87.80%
Trailing Return on Equity
Technical Trend
RSI 14
81.5
SMA50: $74.59
SMA200: $94.70
Valuation Multiplier
Trailing
12.3
Deep Value (Under 15x P/E)
📊
Valuation & Multi-Factor Diagnostic
Deep Value (Under 15x P/E)
ZTS trades at an attractive earnings multiple of 12.3x, significantly lower than the broader S&P 500 average.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线整理 (MA20/50)
Piotroski F-Score: 5/9 (Moderate Financial Health)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1555280 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-08-06 | $2.47B | $691.00M | $1.06B | $1.65 |
| 10-Q | 2025-12-31 | 2026-08-06 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-08-06 | $2.47B | $726.00M | $1.12B | $1.63 |
| 10-Q | 2026-03-31 | 2026-05-07 | $2.26B | $601.00M | $401.00M | $1.42 |
| 10-Q | 2025-03-31 | 2026-05-07 | $2.20B | $602.00M | $515.00M | $1.34 |
| 10-K | 2025-12-31 | 2026-02-12 | $9.47B | $2.67B | $2.90B | $6.02 |
| 10-K | 2024-12-31 | 2026-02-12 | $9.26B | $2.49B | $2.95B | $5.47 |
| 10-K | 2023-12-31 | 2026-02-12 | $8.54B | $2.34B | $2.35B | $5.07 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Zoetis (ZTS) valuation multiples, momentum factors, and point-in-time filing conventions.
How should ZTS's current valuation multiple be interpreted? ↓
ZTS trades at a trailing P/E of 12.3x within the Health Care sector (deep value (under 15x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are ZTS's key momentum and technical factor indicators? ↓
As of the latest close, ZTS shows a 1-month return of +15.31%, 3-month return of +5.34%, and 12-month return of -44.92%, with a 14-day RSI of 81.5. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for ZTS? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can ZTS be incorporated into systematic factor models? ↓
ZTS can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.